Haemophilus parasuis is a Gram-negative bacterium responsible for Glasser's Disease in pigs, though little is known regarding its antigenic or virulence factors. Our goals were to characterize the H. parasuis capsular polysaccharide (CP), determine its role in serotype-specificity and virulence, determine if CP is immunogenic, and develop diagnostic and protective products to prevent rampant H. parasuis infection within swine herds. Material from H. parasuis was purified using carbohydrate isolation techniques and compared to CPs from other Pasteurellaceae. Rabbits were immunized with CPs to generate antisera for microscopy, immunoassays, and bactericidal assays. CP antisera were conjugated to latex particles to create an agglutination assay for detection and typing of H. parasuis. CP was conjugated to Cholera Toxin B, and used to immunize mice and piglets before challenge with H. parasuis to determine its protective efficacy against Glasser's Disease. Broth-grown cells expressed CP, which reacted with antisera in microscopy and immunoassays. Broth-grown H. parasuis cells were serum-resistant unless homologous anti-CP serum was present. In contrast, agar-grown cells did not react with antisera in immunoassays, and cells were susceptible to killing by normal swine serum. CP was not expressed on the surface of agar-grown cells unless supplemented with bicarbonate. The addition of bicarbonate also contributed to the variability in CP quantity and upregulation of genes in the CP locus. Sensitized latex particles agglutinated strongest with homologous H. parasuis CPs, cells, and agar-grown cell lysates, but also reacted weakly with higher concentrations of heterologous CPs. The latex beads did not agglutinate with non-H. parasuis swine bacterial pathogens. Mice immunized with the CP-CTB conjugate produced a significantly higher IgG2/Th2 response than unimmunized mice or mice immunized with only CP, and immunized mice had fewer bacteria in their tissues that unimmunized mice. The CP conjugate produced a robust IgG antibody response to CP when used to immunized piglets, but because the control animals also survived H. parasuis challenge, the protective efficacy remains inconclusive. Therefore, the H. parasuis CP is the antigen that confers serotype identity, and can be implemented in methods and help direct future research in disease prevention and serotype tracking in H. parasuis infections. / Ph. D.

Abstract The purpose of this study was to develop sensitive and specific laboratory diagnostic methods for the demonstration of pneumococcal surface antigens or pneumococcus-specific antibodies in clinical samples. The work took account of epidemiological aspects of both pneumococcal disease and nasopharyngeal carriage of pneumococcus. We first compared the sensitivity of pneumococcal culture and antigen detection methods in nasopharyngeal samples in a developing country setting and then investigated the possibility of improving the sensitivity of the antigen detection by introducing an enrichment step in the procedure. — Further investigations were designed to determine the validity of pneumolysin-specific immune complex bound antibody assay as a tool for diagnosing pneumococcal ALRI in a developing country setting. Finally, we developed an enzyme immunoassay for the detection of pneumococcal capsular polysaccharide antigens, using type-specific antibodies produced in-house in rabbits through immunisation with an in-house-produced pneumococcal whole cell vaccine. The method was tested in nasopharyngeal and middle ear fluid samples. The first results indicated that antigen detection might be more sensitive than culture in demonstrating pneumococci in URT, particularly in children with prior antimicrobial therapy. Antigen detection is a feasible method for studies on pneumococci in developing countries. For type-specific demonstration of S. pneumoniae, detection of pneumococcal antigen after an enrichment step proved a sensitive method that can be applied for epidemiologic study purposes, e.g., in vaccine trials, in areas without ready access to a good microbiology laboratory. Determination of IC-bound pneumolysin IgG antibodies appears to be a useful method for species-specific diagnosis of pneumococcal infections. The results indicating pneumococcal aetiology in ALRI patients in this study compare well with the best results obtained by the use of lung aspirates. Increasing the number of serial samples improves the sensitivity of the assay, but even two samples provide more positive findings than other methods currently in routine use. Criteria of positivity need to be confirmed in subsequent larger studies with both healthy controls and patients with confirmed pneumococcal disease. It is also important to control the findings in patients with pneumonia of non-pneumococcal origin. The novel enzyme immunoassay was shown to work well with enrichment culture samples, with an almost 100% sensitivity compared with the culture. Middle ear fluid samples were too diluted for the enzyme immunoassay method used, and only 74% sensitivity compared with culture was achieved. Provided that adequate samples can be obtained, the method will be a useful complement to the current laboratory methods used to diagnose pneumococcal disease. With the existence of a broad spectrum of microbiological and immunological methods, it is imperative to seek international consensus for standard methods to demonstrate pneumococcus. Otherwise it is very difficult to compare results from different clinical studies. A WHO Working Group recently proposed a standard method for detecting upper respiratory carriage of pneumococcus, but a lot of work remains to be done in other areas of research on pneumococcal infections.

No description available.

Streptococcus pneumoniae é uma bactéria encapsulada causadora de doenças infecciosas como pneumonia, bacteremia e meningite, infecções essas que estão entre as principais causas de morte entre crianças, idosos e imunodeprimidos, indivíduos que constituem o grupo de risco para tais infecções. A vacinação tem sido a mais eficaz forma de conter tais infecções. A vantagem das vacinas conjugadas em comparação às polissacarídicas é a capacidade de indução de uma resposta imune T-dependente o que garante proteção mesmo ao grupo de risco para infecções por S. pneumonia. A proposta do projeto foi estabelecer um protocolo para obtenção de um conjugado constituído pelo polissacarídeo capsular de S. pneumonia sorotipo 1 (PS1) e pela proteína de superfície pneumocócica A (PspA). A síntese do conjugado empregou uma metodologia inédita para o sorotipo 1. A avaliação da resposta imune humoral induzida pelo conjugado mostrou a indução de IgG anti-PS1 gerada pelas imunizações com o conjugado PS1-PspA. / Streptococcus pneumoniae is an encapsulated bacteria causing infectious diseases such as pneumonia, bacteremia and meningitis, these infections are among the leading causes of death among children, elderly and immunocompromised, who constituting individuals of risk group. The vaccination has been the more effective form to counter these infection. The advantage of conjugated vaccines compared to vaccines polysaccharide, is the ability to induce a T-dependent immune response which provides protection even at risk groups for infection by S. pneumoniae. The project proposal was establish a protocol for obtaining a conjugate consisting of the capsular polysaccharide of S. pneumoniae serotype 1 (PS1) and the pneumococcal surface protein A (PspA). The synthesis of conjugate employed a new methodology for serotype 1. The evaluation of humoral immune response induced by the conjugate showed anti-PS1 IgG induction generated by immunization with the PS1-PspA.

No description available.

Cette thèse issue d'une collaboration entre l'Université Lyon 1 et Sanofi Pasteur (SP) porte sur l'étude du procédé de dépolymérisation et d'activation d'un polyoside capsulaire. Cette réaction est la première étape du couplage d'un vaccin (Menactra®) antiméningococcique conjugué (polyoside du méningocoque de groupe C conjugué à l'anatoxine diphtérique). L'objectif de ce travail, réalisé dans le cadre d'un programme d'amélioration de la conformité et de la robustesse des procédés de SP, est la compréhension du mécanisme et l'optimisation des paramètres clés de cette réaction. Le procédé de couplage de ce vaccin tel qu'il est décrit par SP comporte 3 étapes clés : la dépolymérisation/activation du polyoside par le peroxyde d'hydrogène, la dérivatisation par un "linker" et le greffage à la protéine. Si les 2 dernières étapes sont des réactions chimiques bien connues, la première qui permet, à la fois de réduire la masse molaire du polyoside et de générer des groupements réducteurs, est plus obscure. Une stratégie a été élaborée afin de comprendre cette réaction. Dans un premier temps, l'étude poussée du procédé a permis d'identifier les paramètres impactant la cinétique de dépolymérisation et l'activité réductrice. Ensuite, l'analyse structurale, par diverses techniques, du polyoside dépolymérisé a confirmé l'activation. Enfin, la caractérisation de modifications chimiques de macromolécules étant relativement complexe, de plus petits modèles (monomère, tétramère) ont été utilisés et ont permis d'établir un mécanisme réactionnel de la dépolymérisation du polyoside. A partir de ces résultats, plusieurs solutions ont été proposées à l'industriel pour améliorer le rendement et/ou la robustesse du procédé / This PhD work, initiated by Sanofi Pasteur in collaboration with the University of Lyon 1, concerns the study of the Menactra® vaccine, a glycoconjugate vaccine produced by covalently coupling Neisseria meningitidis serogroups A, C, W135, Y capsular polysaccharides to diphtheria toxoid. The objective was to better understand the chemistry involved in the conjugation process of the vaccine, in order to improve the process robustness and the overall conjugated yields with particular emphasis on the serogroup C. The conjugation process can be divided into 3 key steps: depolymerization/activation by hydrogen peroxide, derivatization, and conjugation. While the 2 last steps of the process are well known in bioconjugation chemistry, the exact mechanism of the first step, which serves 2 purposes, first to reduce the polysaccharide molecular weight and second, to generate the reducing groups on the polysaccharide chain, is poorly understood. An overall strategy for the characterization of the serogroup C polysaccharide depolymerization process was successfully applied to understand this reaction. We first provided a process description of this step, identified and optimized the key process parameters. Then, the structural comparison of the polysaccharide before and after the depolymerization obtained with specified analytical methods gave important information on the mechanism. Finally, well defined sialic and tetrasialic acids were reacted with H2O2 to complete the elucidation of this complex mechanism. From these results, several solutions were proposed to the industrial to improve the yield and the robustness

Streptococcus pneumoniae é uma bactéria encapsulada causadora de doenças infecciosas como pneumonia, bacteremia e meningite, infecções essas que estão entre as principais causas de morte entre crianças, idosos e imunodeprimidos, indivíduos que constituem o grupo de risco para tais infecções. A vacinação tem sido a mais eficaz forma de conter tais infecções. A vantagem das vacinas conjugadas em comparação às polissacarídicas é a capacidade de indução de uma resposta imune T-dependente o que garante proteção mesmo ao grupo de risco para infecções por S. pneumonia. A proposta do projeto foi estabelecer um protocolo para obtenção de um conjugado constituído pelo polissacarídeo capsular de S. pneumonia sorotipo 1 (PS1) e pela proteína de superfície pneumocócica A (PspA). A síntese do conjugado empregou uma metodologia inédita para o sorotipo 1. A avaliação da resposta imune humoral induzida pelo conjugado mostrou a indução de IgG anti-PS1 gerada pelas imunizações com o conjugado PS1-PspA. / Streptococcus pneumoniae is an encapsulated bacteria causing infectious diseases such as pneumonia, bacteremia and meningitis, these infections are among the leading causes of death among children, elderly and immunocompromised, who constituting individuals of risk group. The vaccination has been the more effective form to counter these infection. The advantage of conjugated vaccines compared to vaccines polysaccharide, is the ability to induce a T-dependent immune response which provides protection even at risk groups for infection by S. pneumoniae. The project proposal was establish a protocol for obtaining a conjugate consisting of the capsular polysaccharide of S. pneumoniae serotype 1 (PS1) and the pneumococcal surface protein A (PspA). The synthesis of conjugate employed a new methodology for serotype 1. The evaluation of humoral immune response induced by the conjugate showed anti-PS1 IgG induction generated by immunization with the PS1-PspA.

Streptococcus suis est un pathogène porcin et un agent de zoonose en émergence causant des maladies invasives graves. Lorsque la bactérie envahit l’hôte et se retrouve dans le sang, des neutrophiles se mobilisent rapidement pour tenter d’éliminer la menace grâce à de nombreux mécanismes anti-microbiens. Ces cellules sont régulées par le granulocyte colony-stimulating factor (G-CSF) produit lors de l’infection. Il pourrait être un acteur clé du contrôle de l’infection par S. suis mais rien n’est connu sur la production et le rôle du G-CSF dans les infections à S. suis. De plus, le recrutement et l’activation des neutrophiles demeurent peu documentés. L’hypothèse de ce projet est que S. suis induit la production du G-CSF par les cellules de l’immunité innée suite à l’infection, et que le facteur module le recrutement et l’activation des neutrophiles. Cependant, S. suis limite l’activation des cellules immunitaires et se soustrait à l’élimination par les neutrophiles grâce à ses facteurs de virulence. Le 1er objectif consistait à caractériser le recrutement et l’activation des neutrophiles en réponse à S. suis dans un modèle d’infection murin (souris C57BL/6). Nous avons démontré que S. suis cause une mobilisation rapide des neutrophiles de la moelle osseuse vers le sang et la rate. Dans le sang, les neutrophiles présentent un phénotype activé. En parallèle, l’infection cause une élévation spectaculaire du G-CSF systémique, selon un patron similaire à celui des neutrophiles, suggérant un rôle du facteur dans la mobilisation de ces cellules. Le 2e objectif visait à comprendre les mécanismes moléculaires de production de G-CSF. Nous avons donc quantifié le G-CSF produit par différentes cellules immunitaires primaires de souris et démontré que les cellules dendritiques et les macrophages produisent du G-CSF en réponse à S. suis. Les cellules reconnaissent la bactérie par l’intermédiaire de leur Toll-like receptor (TLR) 2 et de récepteurs intracellulaires, ce qui engage des voies de signalisation clés pour la production de médiateurs pro-inflammatoires. Le 3e objectif consistait à élucider le rôle du G-CSF dans le recrutement et l’activation des neutrophiles lors de l’infection par S. suis, et les conséquences sur la pathogenèse. Dans unmodèle d’infection murin, nous avons démontré que le G-CSF cause la sortie des neutrophiles de la moelle osseuse vers le sang, sans que cela augmente l’élimination de la bactérie et la réponse inflammatoire. In vitro, S. suis active peu les neutrophiles porcins, et le G-CSF ne permet pas d’augmenter leurs fonctions. Le 4e objectif avait pour but de déterminer si certains facteurs bactériens de S. suis modulent la production de G-CSF et l’activation des neutrophiles. En utilisant des mutants et des composants bactériens purifiés, nous avons démontré que pour produire le G-CSF, les cellules dendritiques et les macrophages murins reconnaissent les lipoprotéines de S. suis. Cependant, celles-ci sont partiellement masquées par la capsule qui entoure la bactérie, limitant la production de la cytokine. De la même manière, la capsule gêne l’activation optimale des neutrophiles porcins ce qui empêche leur effet bactéricide. Une meilleure compréhension de la pathogenèse des infections à S. suis pourrait orienter de nouvelles stratégies thérapeutiques en lien avec les neutrophiles pour lutter contre la bactérie. Par exemple, le G-CSF couplé à des d’autres immunomodulateurs pourra être envisagé comme traitement métaphylactique dans les élevages porcins pour prévenir d’éventuelles éclosions. / Streptococcus suis is a porcine pathogen and an emerging zoonotic agent causing severe invasive diseases. When the bacterium invades the host and enters the bloodstream, neutrophils quickly mobilize to try to eliminate the threat through various antimicrobial mechanisms. These cells are regulated by granulocyte colony-stimulating factor (G-CSF), which is produced during the infection. It could be a key player in controlling S. suis infection, but nothing is known about the production and role of G-CSF in S. suis infections. Furthermore, neutrophil recruitment and activation remain poorly documented. The hypothesis of this project is that S. suis induces G-CSF production by innate immune cells following infection, and the factor modulates the recruitment and activation of neutrophils. Nevertheless, S. suis prevents immune cells activation and evades elimination by neutrophils due to its virulence factors. The first objective was to characterize the recruitment and activation of neutrophils in response to S. suis in a murine infection model (C57BL/6). We demonstrated that S. suis infection causes a rapid release of neutrophils from the bone marrow to the blood and spleen. In the blood, neutrophils exhibit an activated phenotype. Simultaneously, the infection causes a dramatic increase in systemic G-CSF, following a pattern similar to that of neutrophils, suggesting a role for the factor in the mobilization of these cells. The second objective aimed to understand the molecular mechanisms of G-CSF production. We quantified G-CSF produced by different primary mouse immune cells and showed that dendritic cells and macrophages produce G-CSF in response to S. suis. Cells recognize the bacterium through their Toll-like receptor (TLR) 2 and intracellular receptors, engaging key signaling pathways for pro-inflammatory mediator production. The third objective was to elucidate the role of G-CSF in the recruitment and activation of neutrophils during S. suis infection, and its consequences for pathogenesis. In a murine model, we demonstrated that G-CSF causes the release of neutrophils from the bone marrow into the blood, without increasing bacterial clearance and inflammatory response. In vitro, S. suis weakly activates porcine neutrophils, and G-CSF does not enhance the cellular functions. The fourth objective aimed to determine if certain bacterial factors of S. suis modulate G-CSF production and neutrophil activation. Using mutants and purified bacterial components, we demonstrated that dendritic cells and murine macrophages recognize S. suis lipoproteins to produce G-CSF. However, these lipoproteins are partially masked by the bacterium's capsule, limiting cytokine production. Similarly, the capsule hinders optimal activation of porcine neutrophils, preventing their bactericidal effect. A better understanding of the pathogenesis of S. suis infections could guide new therapeutic strategies related to neutrophils to combat the bacterium. For example, G-CSF combined with other immunomodulators could be considered as a metaphylactic treatment in pig farming to prevent potential outbreaks.

Le Streptocoque de groupe B (GBS) est un important agent d’infection invasive pouvant mener à la mort et demeure la cause principale de septicémie néonatale à ce jour. Neuf sérotypes ont été officiellement décrits basés sur la composition de la capsule polysaccharidique (CPS). Parmi ces sérotypes, le type III est considéré le plus virulent et fréquemment associé aux maladies invasives graves, telle que la méningite. Malgré que plusieurs recherches aient été effectuées au niveau des interactions entre GBS type III et les cellules du système immunitaire innées, aucune information n’est disponible sur la régulation de la réponse immunitaire adaptative dirigée contre ce dernier. Notamment, le rôle de cellules T CD4+ dans l’immuno-pathogenèse de l’infection causée par GBS n’a jamais été étudié. Dans cet étude, trois différents modèles murins d’infection ont été développé pour évaluer l’activation et la modulation des cellules T CD4+ répondantes au GBS de type III : ex vivo, in vivo, et in vitro. Les résultats d’infections ex vivo démontrent que les splénocytes totaux répondent à l’infection en produisant des cytokines de type-1 pro-inflammatoires. Une forte production d’IL-10 accompagne cette cascade inflammatoire, probablement dans l’effort de l’hôte de maintenir l’homéostasie. Les résultats démontrent aussi que les cellules T sont activement recrutées par les cellules répondantes du système inné en produisant des facteurs chimiotactiques, tels que CXCL9, CXCL10, et CCL3. Plus spécifiquement, les résultats obtenus à partir des cellules isolées T CD4+ provenant des infections ex vivo ou in vivo démontrent que ces cellules participent à la production d’IFN-γ et de TNF-α ainsi que d’IL-2, suggérant un profil d’activation Th1. Les cellules isolées T CD4+ n’étaient pas des contributeurs majeurs d’IL-10. Ceci indique que cette cytokine immuno-régulatrice est principalement produite par les cellules de l’immunité innée de la rate de souris infectées. Le profil Th1 des cellules T CD4+ a été confirmé en utilisant un modèle in vitro. Nos résultats démontrent aussi que la CPS de GBS a une role immuno-modulateur dans le développement de la réponse Th1. En résumé, cette étude adresse pour la première fois, la contribution des cellules T CD4+ dans la production d’IFN-γ lors d’une infection à GBS et donc, dans le développement d’une réponse de type Th1. Ces résultats renforcent d’avantage le rôle central de cette cytokine pour un control efficace des infections causées par ce pathogène. / Group B Streptococcus (GBS) is an important agent of life-threatening invasive infections and remains the leading cause of neonatal sepsis to this day. Nine serotypes have been officially described based on capsular polysaccharide (CPS) composition. Among them, capsular type III is considered one of the most virulent and frequently associated with severe invasive diseases, such as meningitis. Although extensive research has been done on the interactions between GBS type III and various cells of the innate immune system, no information is available on the regulation of the adaptive immune response against this pathogen. In particular, the role of CD4+ T cells in the immuno-pathogenesis of the infection caused by GBS has never been assessed. In this study, three different models of murine infection were developed to evaluate activation and modulation of responding CD4+ T cells against GBS type III: ex vivo, in vivo, and in vitro. Ex vivo analysis of total splenocytes showed that GBS induces the release of type-1 pro-inflammatory cytokines. A strong IL-10 production follows this inflammatory cascade, indicating the host effort to maintain homeostasis. Results also indicate that T cells were actively recruited by responding innate immune cells via the release of chemotactic factors such as CXCL9, CXCL10, and CCL3. More specifically, results obtained from isolated CD4+ T cells from ex vivo or in vivo infections showed that they actively participate in the production of IFN-γ and TNF-α, as well as IL-2, suggesting a Th1 profile of activation. On the other hand, isolated CD4+ T cells were not main sources of IL-10. This observation suggests that this immuno-regulatory cytokine is produced mainly by cells of the spleen innate immune system of infected animals. The CD4+ Th1 cell profile was confirmed using an in vitro model of infection. Our results also suggest that the GBS CPS plays an immuno-modulatory role in the development of a Th1 response. In summary, this study addresses for this first time the contribution of CD4+ T cells in IFN-γ production during GBS infection, and thus, in the development of a Th1 response. Our data further highlight the central role of this cytokine for effective control of GBS infections.

No description available.